ID   HMy.2 B
AC   CVCL_8119
SY   LICR-Lon-HMy-2; LICR-LON-HMy2; LICR.LON.HMy2; Licr.Lon.Hmy2; LICRLON/My2; Hmy2; LICR-2
DR   CLS; 302008
DR   IPD-IMGT/HLA; 10744
DR   TKG; TKG 0221
DR   Wikidata; Q54889980
RX   DOI=10.1007/978-1-4613-2823-0_29;
RX   Patent=US4695538;
RX   PubMed=6350451;
RX   PubMed=6582512;
RX   PubMed=6864164;
RX   PubMed=7140810;
CC   Group: Hybridoma fusion partner cell line.
CC   Population: Caucasian.
CC   Doubling time: 24 hours (Patent=US4695538).
CC   HLA typing: A*02:01; B*35:03; C*04:01 (IPD-IMGT/HLA=10744).
CC   HLA typing: A*02:01:01,03:01:01; B*15:01:01,35:03:01; C*03:04:01,04:01:01; DPB1*03:01:01,04:01:01; DQA1*03:01:01,05:05:01; DQB1*03:01:01,03:02:01; DRB1*04:01:01,12:01:01 (CLS=302008).
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): CLS; TKG
ST   Amelogenin: X
ST   CSF1PO: 6,10
ST   D13S317: 11,13
ST   D16S539: 9,13 (TKG)
ST   D16S539: 13 (CLS)
ST   D18S51: 4,16
ST   D19S433: 14,15
ST   D21S11: 29,30
ST   D2S1338: 17
ST   D3S1358: 16
ST   D5S818: 10,13
ST   D7S820: 7,12
ST   D8S1179: 14,15
ST   FGA: 20,21
ST   TH01: 8,9.3
ST   TPOX: 8
ST   vWA: 17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1072 ! ARH-77
SX   Female
AG   33Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 21
//
RX   DOI=10.1007/978-1-4613-2823-0_29;
RA   Karpas A.;
RT   "Viruses and human leukemia in vitro.";
RL   (In) Human leukemia. Cytochemical and ultrastructural techniques in diagnosis and research. Developments in Oncology, Vol. 14; Polliack A. (eds.); pp.495-526; Martinus Nijhoff Publishing; Boston (1984).
//
RX   Patent=US4695538;
RA   Cote R.J., Thomson T.M., Houghton A.N., Oettgen H.F., Old L.J.,
RA   Cardo C.C.;
RT   "Human monoclonal antibodies to cell surface antigens.";
RL   Patent number US4695538, 22-Sep-1987.
//
RX   PubMed=6350451; DOI=10.4049/jimmunol.131.3.1201;
RA   Abrams P.G., Knost J.A., Clarke G., Wilburn S., Oldham R.K.,
RA   Foon K.A.;
RT   "Determination of the optimal human cell lines for development of
RT   human hybridomas.";
RL   J. Immunol. 131:1201-1204(1983).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6864164; DOI=10.1084/jem.158.1.53;
RA   Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F.,
RA   Old L.J.;
RT   "Detection of cell surface and intracellular antigens by human
RT   monoclonal antibodies. Hybrid cell lines derived from lymphocytes of
RT   patients with malignant melanoma.";
RL   J. Exp. Med. 158:53-65(1983).
//
RX   PubMed=7140810; DOI=10.1002/eji.1830120804;
RA   Edwards P.A.W., Smith C.M., Neville A.M., O'Hare M.J.;
RT   "A human-hybridoma system based on a fast-growing mutant of the ARH-77
RT   plasma cell leukemia-derived line.";
RL   Eur. J. Immunol. 12:641-648(1982).
//